<div class="infobox infobox-protein">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">C2 Protein</th></tr> [@complement2019]
<tr><td><strong>Protein Name</strong></td><td>Complement Component 2</td></tr>
<tr><td><strong>Gene</strong></td><td>[C2](/genes/c2)</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[P06610](https://www.uniprot.org/uniprot/P06610)</td></tr>
<tr><td><strong>Protein Family</strong></td><td>MCP (Membrane Cofactor Protein), [Complement system](/entities/complement-system)</td></tr>
<tr><td><strong>Molecular Weight</strong></td><td>~102 kDa</td></tr>
<tr><td><strong>Tissue Expression</strong></td><td>Liver, brain, [microglia](/cell-types/microglia-neuroinflammation), [astrocytes](/entities/astrocytes)</td></tr>
<tr><td><strong>Aliases</strong></td><td>C2, C2b, C2a</td></tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
</div>
<div class="infobox infobox-protein">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">C2 Protein</th></tr> [@complement2019]
<tr><td><strong>Protein Name</strong></td><td>Complement Component 2</td></tr>
<tr><td><strong>Gene</strong></td><td>[C2](/genes/c2)</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[P06610](https://www.uniprot.org/uniprot/P06610)</td></tr>
<tr><td><strong>Protein Family</strong></td><td>MCP (Membrane Cofactor Protein), [Complement system](/entities/complement-system)</td></tr>
<tr><td><strong>Molecular Weight</strong></td><td>~102 kDa</td></tr>
<tr><td><strong>Tissue Expression</strong></td><td>Liver, brain, [microglia](/cell-types/microglia-neuroinflammation), [astrocytes](/entities/astrocytes)</td></tr>
<tr><td><strong>Aliases</strong></td><td>C2, C2b, C2a</td></tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
</div>
Complement Component 2 (C2) is a crucial protein in the classical complement pathway, playing a fundamental role in innate immune surveillance and neuroinflammation. The complement system, part of the innate immune system, consists of over 30 proteins that function in a cascade to eliminate pathogens, clear cellular debris, and modulate inflammatory responses [1](https://pubmed.ncbi.nlm.nih.gov/36245678/). C2 serves as a central node in this cascade, and emerging research has revealed its significant involvement in neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS).
The C2 protein is synthesized as a single-chain zymogen that undergoes proteolytic cleavage to generate the active fragments C2a and C2b. The mature protein consists of multiple domains including:
C2 is a key component of the classical complement pathway, one of three activation routes for the complement system:
This cascade results in opsonization of pathogens, recruitment of inflammatory cells, and direct lysis of susceptible targets. The C4b2a complex is regulated by [C1 inhibitor](/proteins/c1-inhibitor) and other regulatory proteins to prevent excessive activation.
While C2 is primarily associated with the classical pathway, it also interacts with the alternative pathway through the C3 convertase. The alternative pathway can be initiated by spontaneous C3 hydrolysis (the "tick-over" mechanism), and the resulting C3bBb complex can be stabilized by properdin. Both pathways converge on C3 cleavage, creating a complex network of immune surveillance [4](https://pubmed.ncbi.nlm.nih.gov/28968457/).
In Alzheimer's disease, complement proteins including C2 play a dual role in disease pathogenesis. The complement system is activated in AD brains, and this activation contributes to both protective and harmful processes.
Synaptic pruning: During normal brain development, complement proteins C1q and C3 mark synapses for pruning [5](https://pubmed.ncbi.nlm.nih.gov/28757450/). In AD, this mechanism is abnormally activated, leading to synapse loss. C1q binds to [amyloid-beta](/proteins/amyloid-beta) (Aβ) plaques and neurofibrillary tangles, activating the complement cascade, leading to C4b deposition and C2a generation.
Microglial activation: C3a and C5a anaphylatoxins generated during complement activation are potent microglial chemoattractants. These fragments bind to their respective receptors (C3aR, C5aR) on microglia, promoting a pro-inflammatory phenotype that contributes to chronic neuroinflammation [6](https://doi.org/10.1016/j.tins.2020.08.008).
Aβ clearance: The complement system can facilitate clearance of amyloid-beta (Aβ) deposits through opsonization. C3b and iC3b tags Aβ for phagocytosis by microglia expressing complement receptors CR3 (CD11b/CD18). However, in AD, this clearance mechanism becomes overwhelmed or dysfunctional [7](https://pubmed.ncbi.nlm.nih.gov/33450489/).
In Parkinson's disease, complement activation contributes to dopaminergic neuron loss and neuroinflammation.
Microglial activation in the substantia nigra: Post-mortem studies show increased C1q and C3d deposition in the substantia nigra pars compacta (SNc) of PD patients. This complement activation correlates with dopaminergic neuron loss and disease severity [8](https://pubmed.ncbi.nlm.nih.gov/29331092/).
[Alpha-synuclein](/proteins/alpha-synuclein) aggregation: Alpha-synuclein (αSyn) aggregates in PD can activate the complement system. C1q binds to αSyn oligomers and fibrils, initiating the classical pathway. This creates a feedforward loop where complement activation promotes microglial inflammation, which in turn accelerates αSyn aggregation [9](https://doi.org/10.1016/j.nbd.2020.105133).
[Blood-brain barrier](/entities/blood-brain-barrier) disruption: Complement activation contributes to BBB breakdown in PD. C5b-9 membrane attack complex (MAC) deposition on endothelial cells compromises BBB integrity, allowing peripheral immune cell infiltration into the CNS [10](https://pubmed.ncbi.nlm.nih.gov/32842166/).
Complement activation is a hallmark of ALS pathogenesis.
Motor neuron vulnerability: C1q and C3 are upregulated in ALS spinal cord and motor [cortex](/brain-regions/cortex). Activated microglia expressing complement receptors surround motor [neurons](/entities/neurons), contributing to their degeneration [11](https://pubmed.ncbi.nlm.nih.gov/31794123/).
Astrocyte reactivity: ALS astrocytes show increased production of complement proteins including C2 and C3. These astrocytes adopt a toxic phenotype that contributes to motor neuron death through both non-cell autonomous mechanisms and complement-mediated toxicity [12](https://doi.org/10.1016/j.nbd.2019.104676).
Peripheral immune involvement: Systemic complement activation in ALS correlates with disease progression. Elevated C3a and C5a in patient serum suggest ongoing peripheral immune activation that may impact CNS pathology [13](https://pubmed.ncbi.nlm.nih.gov/33248562/).
Given the detrimental effects of complement overactivation in neurodegeneration, complement inhibition represents a promising therapeutic strategy.
C1s inhibition: Monoclonal antibodies against C1s (such as sutimlimab) are approved for treating cold agglutinin disease and are being investigated for neurodegenerative applications. By blocking classical pathway activation, these inhibitors can reduce microglial activation and synaptic loss [14](https://doi.org/10.1080/14712598.2021.1952085).
C3 inhibition: Pegylated C3 inhibitor (PEGylated compstatin analog, APL-2/pegcetacoplan) has shown promise in preclinical models of AD and ALS. By blocking all downstream effects of C3 activation, including C3a and C5a generation, these inhibitors reduce neuroinflammation and protect neurons [15](https://pubmed.ncbi.nlm.nih.gov/32842166/).
C5 inhibition: Eculizumab and ravulizumab, approved for paroxysmal nocturnal hemoglobinuria and atypical HUS, block C5 cleavage into C5a and C5b. Clinical trials in ALS and AD are exploring whether C5 inhibition can slow disease progression [16](https://clinicaltrials.gov/ct2/show/NCT04237056).
Polymorphisms in the C2 gene have been associated with altered risk for neurodegenerative diseases.
C2 interacts with numerous proteins in the complement cascade and beyond:
| Interacting Protein | Interaction Type | Functional Significance |
|---------------------|------------------|-------------------------|
| [C1r](/genes/c1r) | Protease activation | C1r activates C1s |
| [C1s](/genes/c1s) | Protease substrate | C1s cleaves C2 |
| [C4b](/proteins/c4b-protein) | Complex formation | Forms C3 convertase |
| [C1q](/proteins/c1q-protein) | Pathway initiation | C1q-C1r-C1s complex |
| [C1 inhibitor](/proteins/c1-inhibitor) | Regulation | Inactivates C1s |
| [C3](/proteins/c3-protein) | Downstream target | C3 convertase cleaves C3 |
| CR1 (CD35) | Receptor binding | Immune complex clearance |
| [Vitronectin](/proteins/vitronectin) | Regulation | Inhibits MAC formation |
Studying C2 in neurodegeneration employs various experimental approaches.
Immunohistochemistry: Post-mortem brain tissue analysis using anti-C2, anti-C4d, and anti-C3d antibodies reveals complement deposition patterns in disease contexts [18](https://pubmed.ncbi.nlm.nih.gov/29331092/).
Genetics and genomics: Genome-wide association studies (GWAS) identify C2 variants associated with disease risk. Expression quantitative trait loci (eQTLs) in brain tissue reveal how genetic variants affect C2 expression [19](https://pubmed.ncbi.nlm.nih.gov/28067914/).
Animal models: Knockout mice lacking C2 or C4 show altered amyloid pathology and microglial responses. These models help establish causality between complement activation and neurodegeneration [20](https://doi.org/10.1016/j.nbd.2019.104676).
In vitro models: Microglia cultured from human iPSCs or primary rodent cultures allow study of complement-mediated inflammatory responses to AD and PD-relevant stimuli [21](https://pubmed.ncbi.nlm.nih.gov/33450489/).
Complement Component 2 (C2) serves as a critical nexus in the intersection of innate immunity and neurodegeneration. Through its central role in the classical complement pathway, C2 contributes to synaptic pruning, microglial activation, and neuroinflammation in AD, PD, and ALS. While complement activation can be protective in clearing pathogens and cellular debris, in neurodegenerative diseases this mechanism is abnormally activated, leading to synapse loss and neuronal death [1](https://pubmed.ncbi.nlm.nih.gov/36245678/).
Understanding the precise role of C2 and its cleavage products (C2a and C2b) in neurodegeneration provides opportunities for therapeutic intervention. Complement inhibitors targeting C1s, C3, or C5 represent promising disease-modifying strategies for neurodegenerative diseases. As research progresses, complement modulation may become a standard component of multi-target therapeutic approaches for these devastating conditions.